Monocyclic L-nucleosides, analogs and uses thereof

• US 6,642,206 B2
• Filed: 04/09/2002
• Issued: 11/04/2003
• Est. Priority Date: 10/16/1996
• Status: Expired due to Term

• Current Assignee: Ribapharm Inc. (Bausch Health Cos., Inc.)
• Original Assignee: ICN Pharmaceuticals, Inc (Bausch Health Cos., Inc.)
• Inventors: Ramasamy, Kanda, Tam, Robert, Averett, Devron
• Primary Examiner(s): CRANE, LAWRENCE E
• Application Number:
  US10/120,101
• Publication Number:
  US 20030018186A1
• Time in Patent Office: 574 Days
• Field of Search: 536/28.7, 514/43
• US Class Current: 514/43
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C07H 19/04 Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Abstract

Novel monocyclic L-Nucleoside compounds have the general formula

Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.

Claims

1. A compound having a structure according to Formula I:

and pharmaceutically acceptable salts thereof.

2. The compound of claim 1 consisting of one of the salts.

3. The compound according to claim 2 having a structure according to Formula II:

4. The compound of claim 1 wherein the triazole heterocyclic base is in beta configuration relative to the ribose sugar.

5. A pharmaceutcal composition comprising a compound according to any one of claims 1, 2, 3, or 4 or a pharmaceutcally acceptable ester or prodrug thereof, admixed with at least one pharmaceutically acceptable carrier.